Literature DB >> 25405392

Atenolol versus losartan in children and young adults with Marfan's syndrome.

Ronald V Lacro1, Harry C Dietz, Lynn A Sleeper, Anji T Yetman, Timothy J Bradley, Steven D Colan, Gail D Pearson, E Seda Selamet Tierney, Jami C Levine, Andrew M Atz, D Woodrow Benson, Alan C Braverman, Shan Chen, Julie De Backer, Bruce D Gelb, Paul D Grossfeld, Gloria L Klein, Wyman W Lai, Aimee Liou, Bart L Loeys, Larry W Markham, Aaron K Olson, Stephen M Paridon, Victoria L Pemberton, Mary Ella Pierpont, Reed E Pyeritz, Elizabeth Radojewski, Mary J Roman, Angela M Sharkey, Mario P Stylianou, Stephanie Burns Wechsler, Luciana T Young, Lynn Mahony.   

Abstract

BACKGROUND: Aortic-root dissection is the leading cause of death in Marfan's syndrome. Studies suggest that with regard to slowing aortic-root enlargement, losartan may be more effective than beta-blockers, the current standard therapy in most centers.
METHODS: We conducted a randomized trial comparing losartan with atenolol in children and young adults with Marfan's syndrome. The primary outcome was the rate of aortic-root enlargement, expressed as the change in the maximum aortic-root-diameter z score indexed to body-surface area (hereafter, aortic-root z score) over a 3-year period. Secondary outcomes included the rate of change in the absolute diameter of the aortic root; the rate of change in aortic regurgitation; the time to aortic dissection, aortic-root surgery, or death; somatic growth; and the incidence of adverse events.
RESULTS: From January 2007 through February 2011, a total of 21 clinical centers enrolled 608 participants, 6 months to 25 years of age (mean [±SD] age, 11.5±6.5 years in the atenolol group and 11.0±6.2 years in the losartan group), who had an aortic-root z score greater than 3.0. The baseline-adjusted rate of change in the mean (±SE) aortic-root z score did not differ significantly between the atenolol group and the losartan group (-0.139±0.013 and -0.107±0.013 standard-deviation units per year, respectively; P=0.08). Both slopes were significantly less than zero, indicating a decrease in the aortic-root diameter relative to body-surface area with either treatment. The 3-year rates of aortic-root surgery, aortic dissection, death, and a composite of these events did not differ significantly between the two treatment groups.
CONCLUSIONS: Among children and young adults with Marfan's syndrome who were randomly assigned to losartan or atenolol, we found no significant difference in the rate of aortic-root dilatation between the two treatment groups over a 3-year period. (Funded by the National Heart, Lung, and Blood Institute and others; ClinicalTrials.gov number, NCT00429364.).

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25405392      PMCID: PMC4386623          DOI: 10.1056/NEJMoa1404731

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  26 in total

1.  Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome.

Authors:  Delphine Detaint; Philippe Aegerter; Florence Tubach; Isabelle Hoffman; Henri Plauchu; Yves Dulac; Laurence Olivier Faivre; Marie-Ange Delrue; Patrick Collignon; Sylvie Odent; Maria Tchitchinadze; Catherine Bouffard; Florence Arnoult; Mathieu Gautier; Catherine Boileau; Guillaume Jondeau
Journal:  Arch Cardiovasc Dis       Date:  2010-07-01       Impact factor: 2.340

2.  [Study of the efficacy and safety of losartan versus atenolol for aortic dilation in patients with Marfan syndrome].

Authors:  Alberto Forteza; Arturo Evangelista; Violeta Sánchez; Gisela Teixidó; Diana García; Paz Sanz; Laura Gutiérrez; Jorge Centeno; José Rodríguez-Palomares; José Cortina; David García-Dorado
Journal:  Rev Esp Cardiol       Date:  2011-05-10       Impact factor: 4.753

3.  Characteristics of children and young adults with Marfan syndrome and aortic root dilation in a randomized trial comparing atenolol and losartan therapy.

Authors:  Ronald V Lacro; Lin T Guey; Harry C Dietz; Gail D Pearson; Anji T Yetman; Bruce D Gelb; Bart L Loeys; D Woodrow Benson; Timothy J Bradley; Julie De Backer; Geoffrey A Forbus; Gloria L Klein; Wyman W Lai; Jami C Levine; Mark B Lewin; Larry W Markham; Stephen M Paridon; Mary Ella Pierpont; Elizabeth Radojewski; Elif Seda Selamet Tierney; Angela M Sharkey; Stephanie Burns Wechsler; Lynn Mahony
Journal:  Am Heart J       Date:  2013-03-26       Impact factor: 4.749

4.  The Ghent Marfan Trial--a randomized, double-blind placebo controlled trial with losartan in Marfan patients treated with β-blockers.

Authors:  Katarina Möberg; Sylvia De Nobele; Dan Devos; Els Goetghebeur; Patrick Segers; Bram Trachet; Chris Vervaet; Marjolijn Renard; Paul Coucke; Bart Loeys; Anne De Paepe; Julie De Backer
Journal:  Int J Cardiol       Date:  2011-01-15       Impact factor: 4.164

5.  Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome.

Authors:  Jennifer P Habashi; Daniel P Judge; Tammy M Holm; Ronald D Cohn; Bart L Loeys; Timothy K Cooper; Loretha Myers; Erin C Klein; Guosheng Liu; Carla Calvi; Megan Podowski; Enid R Neptune; Marc K Halushka; Djahida Bedja; Kathleen Gabrielson; Daniel B Rifkin; Luca Carta; Francesco Ramirez; David L Huso; Harry C Dietz
Journal:  Science       Date:  2006-04-07       Impact factor: 47.728

Review 6.  Lessons on the pathogenesis of aneurysm from heritable conditions.

Authors:  Mark E Lindsay; Harry C Dietz
Journal:  Nature       Date:  2011-05-19       Impact factor: 49.962

7.  Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study.

Authors:  Hsin-Hui Chiu; Mei-Hwan Wu; Jou-Kou Wang; Chun-Wei Lu; Shuenn-Nan Chiu; Chun-An Chen; Ming-Tai Lin; Fu-Chang Hu
Journal:  Mayo Clin Proc       Date:  2013-01-12       Impact factor: 7.616

8.  Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome.

Authors:  Ronald V Lacro; Harry C Dietz; Lisa M Wruck; Timothy J Bradley; Steven D Colan; Richard B Devereux; Gloria L Klein; Jennifer S Li; L LuAnn Minich; Stephen M Paridon; Gail D Pearson; Beth F Printz; Reed E Pyeritz; Elizabeth Radojewski; Mary J Roman; J Philip Saul; Mario P Stylianou; Lynn Mahony
Journal:  Am Heart J       Date:  2007-10       Impact factor: 4.749

9.  Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations.

Authors:  Fabiana I Gambarin; Valentina Favalli; Alessandra Serio; Mario Regazzi; Michele Pasotti; Catherine Klersy; Roberto Dore; Savina Mannarino; Mario Viganò; Attilio Odero; Simona Amato; Luigi Tavazzi; Eloisa Arbustini
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2009-04       Impact factor: 2.160

10.  TGF-beta in the pathogenesis and prevention of disease: a matter of aneurysmic proportions.

Authors:  Harry C Dietz
Journal:  J Clin Invest       Date:  2010-01-25       Impact factor: 14.808

View more
  143 in total

1.  Fibrillin-containing microfibrils are key signal relay stations for cell function.

Authors:  Karina A Zeyer; Dieter P Reinhardt
Journal:  J Cell Commun Signal       Date:  2015-10-08       Impact factor: 5.782

2.  Abnormal mechanosensing and cofilin activation promote the progression of ascending aortic aneurysms in mice.

Authors:  Yoshito Yamashiro; Christina L Papke; Jungsil Kim; Lea-Jeanne Ringuette; Qing-Jun Zhang; Zhi-Ping Liu; Hamid Mirzaei; Jessica E Wagenseil; Elaine C Davis; Hiromi Yanagisawa
Journal:  Sci Signal       Date:  2015-10-20       Impact factor: 8.192

3.  Standing tall after DeBakey Type I aortic dissection extending to left iliac artery.

Authors:  Deepak Natarajan; Nalin Natarajan
Journal:  Indian Heart J       Date:  2015-09-11

Review 4.  Depression as a systemic syndrome: mapping the feedback loops of major depressive disorder.

Authors:  A K Wittenborn; H Rahmandad; J Rick; N Hosseinichimeh
Journal:  Psychol Med       Date:  2015-12-01       Impact factor: 7.723

Review 5.  Molecular, genetic, and cellular bases for treating eosinophilic esophagitis.

Authors:  Marc E Rothenberg
Journal:  Gastroenterology       Date:  2015-02-07       Impact factor: 22.682

6.  Losartan Rescues Inflammation-related Mucociliary Dysfunction in Relevant Models of Cystic Fibrosis.

Authors:  Michael D Kim; Nathalie Baumlin; Makoto Yoshida; Deepika Polineni; Sebastian F Salathe; Joseph K David; Charles A Peloquin; Adam Wanner; John S Dennis; Juliette Sailland; Philip Whitney; Frank T Horrigan; Juan R Sabater; William M Abraham; Matthias Salathe
Journal:  Am J Respir Crit Care Med       Date:  2020-02-01       Impact factor: 21.405

7.  Application of induced pluripotent stem cells to model smooth muscle cell function in vascular diseases.

Authors:  HaYeun Ji; Hye Sung Kim; Hae-Won Kim; Kam W Leong
Journal:  Curr Opin Biomed Eng       Date:  2017-03-22

8.  Health-Related Quality of Life in Children and Young Adults with Marfan Syndrome.

Authors:  Jill C Handisides; Danielle Hollenbeck-Pringle; Karen Uzark; Felicia L Trachtenberg; Victoria L Pemberton; Teresa W Atz; Timothy J Bradley; Elizabeth Cappella; Sylvia De Nobele; Georgeann Keh-Teng Groh; Michelle S Hamstra; Rosalind Korsin; Jami C Levine; Bergen Lindauer; Aimee Liou; Meghan K Mac Neal; Larry W Markham; Tonia Morrison; Kathleen A Mussatto; Aaron K Olson; Mary Ella M Pierpont; Reed E Pyeritz; Elizabeth A Radojewski; Mary J Roman; Mingfen Xu; Ronald V Lacro
Journal:  J Pediatr       Date:  2018-09-27       Impact factor: 4.406

9.  Role of Thrombospondin-1 in Mechanotransduction and Development of Thoracic Aortic Aneurysm in Mouse and Humans.

Authors:  Yoshito Yamashiro; Bui Quoc Thang; Seung Jae Shin; Caroline Antunes Lino; Tomoyuki Nakamura; Jungsil Kim; Kaori Sugiyama; Chiho Tokunaga; Hiroaki Sakamoto; Motoo Osaka; Elaine C Davis; Jessica E Wagenseil; Yuji Hiramatsu; Hiromi Yanagisawa
Journal:  Circ Res       Date:  2018-08-31       Impact factor: 17.367

10.  Postnatal Deletion of the Type II Transforming Growth Factor-β Receptor in Smooth Muscle Cells Causes Severe Aortopathy in Mice.

Authors:  Jie Hong Hu; Hao Wei; Mia Jaffe; Nathan Airhart; Liang Du; Stoyan N Angelov; James Yan; Julie K Allen; Inkyung Kang; Thomas N Wight; Kate Fox; Alexandra Smith; Rachel Enstrom; David A Dichek
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-10-22       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.